DURECT Corp Files 8-K: Material Agreement & Financials
| Field | Detail |
|---|---|
| Company | Durect Corp |
| Form Type | 8-K |
| Filed Date | Aug 8, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-statements
TL;DR
DURECT Corp filed an 8-K on Aug 8, 2025, for a material agreement and financials - details to come.
AI Summary
On August 8, 2025, DURECT Corporation filed an 8-K report detailing a material definitive agreement and financial statements. The filing does not disclose specific details of the agreement or financial figures, but indicates a significant event for the company.
Why It Matters
This filing signals a potentially significant business development or financial update for DURECT Corporation, requiring investor attention.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and financial statements, suggesting significant corporate activity, but lacks specific details, creating uncertainty.
Key Players & Entities
- DURECT CORPORATION (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- August 8, 2025 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement filed by DURECT Corporation?
The filing indicates the entry into a material definitive agreement, but the specific terms and counterparty are not detailed in the provided excerpt.
What financial statements are being filed with this 8-K?
The filing states that financial statements are included, but the specific financial data or period covered is not provided in the excerpt.
When was this 8-K report filed?
The report was filed on August 8, 2025.
What is DURECT Corporation's principal executive office address?
The principal executive offices are located at 10240 Bubb Road, Cupertino, CA 95014.
What is the SIC code for DURECT Corporation?
The Standard Industrial Classification (SIC) code for DURECT Corporation is 2834, Pharmaceutical Preparations.
Filing Stats: 1,508 words · 6 min read · ~5 pages · Grade level 13.4 · Accepted 2025-08-08 17:29:50
Key Financial Figures
- $0.0001 — ange on Which Registered Common Stock $0.0001 par value per share DRRX The NASDAQ
Filing Documents
- d92539d8k.htm (8-K) — 34KB
- d92539dex21.htm (EX-2.1) — 11KB
- 0001193125-25-177114.txt ( ) — 159KB
- drrx-20250808.xsd (EX-101.SCH) — 3KB
- drrx-20250808_lab.xml (EX-101.LAB) — 17KB
- drrx-20250808_pre.xml (EX-101.PRE) — 11KB
- d92539d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 2.1 Amendment No. 1 to the Agreement and Plan of Merger by and among DURECT Corporation, Bausch Health Americas, Inc., BHC Lyon Merger Sub, Inc. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) Additional Information and Where to Find it The Offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell Company Shares. At the time the Offer is commenced, Parent and Merger Sub will file a Tender Offer Statement on Schedule TO with the SEC, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer. The Company stockholders and other investors are urged to read the Offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the Offer. These materials will be sent free of charge to all stockholders of the Company. In addition, all of these materials (and all other materials filed by the Company with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by the Company at https://www.durect.com/investors. Cautionary Statement Regarding Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DURECT Corporation Date: August 8, 2025 By: /s/ James E. Brown James E. Brown President and Chief Executive Officer